152 related articles for article (PubMed ID: 38712312)
1. Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report.
Harada T; Uetani N; Inui G; Ishikawa H; Funaki Y; Takata M; Okazaki R; Yamaguchi K; Morita M; Kitatani S; Yamasaki A
Respir Med Case Rep; 2024; 49():102035. PubMed ID: 38712312
[TBL] [Abstract][Full Text] [Related]
2. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
Baroz AR; Mambetsariev I; Fricke J; Pharaon R; Tan T; Kidambi T; Sandhu KS; Koczywas M; Salgia R
Cureus; 2021 Jul; 13(7):e16266. PubMed ID: 34377604
[TBL] [Abstract][Full Text] [Related]
3. Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor.
Mutoh T; Chikamatsu S; Sasaki T; Seino H; Sakamoto K; Kudo M
JMA J; 2023 Oct; 6(4):552-555. PubMed ID: 37941715
[TBL] [Abstract][Full Text] [Related]
4. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report.
Hamada K; Yoshimura K; Oshinomi K; Hirasawa Y; Ariizumi H; Ohkuma R; Shida M; Kubota Y; Matsui H; Ishiguro T; Sambe T; Ishida H; Horiike A; Wada S; Iwamoto S; Uchida N; Ogawa Y; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2022 Jan; 101(2):e28339. PubMed ID: 35029177
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced "Eosinophilic Fasciitis-Like" Case and a Review of the Literature.
Salamaliki C; Solomou EE; Liossis SC
Rheumatol Ther; 2020 Dec; 7(4):1045-1052. PubMed ID: 33067734
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.
Ishii A; Yokoyama M; Tsuji H; Fujii Y; Tamaoka A
eNeurologicalSci; 2020 Jun; 19():100236. PubMed ID: 32211521
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.
Harada M; Naoi H; Yasuda K; Ito Y; Kagoo N; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Tsukui M; Koshimizu N
BMC Pulm Med; 2021 Jan; 21(1):6. PubMed ID: 33407304
[TBL] [Abstract][Full Text] [Related]
9. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
10. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
11. Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab.
Izumo T; Terada Y; Tone M; Inomata M; Kuse N; Awano N; Moriya A; Jo T; Yoshimura H; Furuhata Y
Respir Med Case Rep; 2019; 26():292-295. PubMed ID: 30859062
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
[TBL] [Abstract][Full Text] [Related]
14. Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review.
Takeda A; Koike W; Watanabe K
Gynecol Oncol Rep; 2020 May; 32():100553. PubMed ID: 32140532
[TBL] [Abstract][Full Text] [Related]
15. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
16. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
17. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
Fionda L; Rossini E; Lauletta A; Leonardi L; Tufano L; Costanzo R; Marchetti P; Salvetti M; Garibaldi M; Morino S; Antonini G
Neurol Sci; 2024 Mar; 45(3):1243-1247. PubMed ID: 38108913
[TBL] [Abstract][Full Text] [Related]
19. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection.
Zhou C; Klionsky Y; Treasure ME; Bruno DS
Case Rep Oncol; 2019; 12(1):164-170. PubMed ID: 31043955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
